CREDENCE ' Knocks Your Socks Off ' ; New Analysis Reported at ADA CREDENCE ' Knocks Your Socks Off ' ; New Analysis Reported at ADA

Latest analysis of CREDENCE with SGLT2 inhibitor canagliflozin shows the agent has a cardio- and renal-protective effect in both primary and secondary CV prevention populations.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news